BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 30594101)

  • 41. Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis.
    Weber S; Haferlach T; Haferlach C; Kern W
    Blood Cancer J; 2016 Dec; 6(12):e507. PubMed ID: 27935581
    [No Abstract]   [Full Text] [Related]  

  • 42. Familial Acute Myeloid Leukemia and Myelodysplasia in Hungary.
    Király AP; Kállay K; Gángó A; Kellner Á; Egyed M; Szőke A; Kiss R; Vályi-Nagy I; Csomor J; Matolcsy A; Bödör C
    Pathol Oncol Res; 2018 Jan; 24(1):83-88. PubMed ID: 28357685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Ghosh K; Madkaikar M
    Leuk Lymphoma; 2016 Sep; 57(9):2195-8. PubMed ID: 26700494
    [No Abstract]   [Full Text] [Related]  

  • 44. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
    J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Distribution of Chromosomal Abnormalities Commonly Observed in Adult Acute Myeloid Leukemia in Pakistan as Predictors of Prognosis.
    Shaikh MS; Ahmed ZA; Shaikh MU; Adil SN; Khurshid M; Moatter T; Rashid A; Karim F; Raheem A; Ali N
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1903-1906. PubMed ID: 30049204
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of galectin-3 in patients with adult acute myeloid leukemia: a retrospective cohort study with long-term follow-up and formulation of risk scoring system.
    Gao N; Yu WZ; Guo NJ; Wang XX; Sun JR
    Leuk Lymphoma; 2017 Jun; 58(6):1394-1402. PubMed ID: 27736291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia.
    Zhou JD; Zhang LC; Zhang TJ; Gu Y; Wu DH; Zhang W; Ma JC; Wen XM; Guo H; Lin J; Qian J
    J Transl Med; 2018 May; 16(1):135. PubMed ID: 29784043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Down-regulation of GPX3 is associated with favorable/intermediate karyotypes in de novo acute myeloid leukemia.
    Zhou JD; Wen XM; Zhang YY; Yang L; Ma YJ; Ma JC; Yang J; Guo H; Yao DM; Lin J; Qian J
    Int J Clin Exp Pathol; 2015; 8(3):2384-91. PubMed ID: 26045745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia.
    Yin JY; Tang Q; Zhai LL; Zhou LY; Qian J; Lin J; Wen XM; Zhou JD; Zhang YY; Zhu XW; Deng ZQ
    Tumour Biol; 2015 Dec; 36(12):9711-6. PubMed ID: 26152287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.
    Damiani D; Tiribelli M; Raspadori D; Sirianni S; Meneghel A; Cavalllin M; Michelutti A; Toffoletti E; Geromin A; Simeone E; Bocchia M; Fanin R
    Oncotarget; 2015 Oct; 6(30):30212-21. PubMed ID: 26338961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The clinical relevance of BAALC and ERG expression levels in pediatric AML.
    Hermkens MC; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Baruchel A; Stary J; Reinhardt D; Zimmerman M; de Haas V; Pieters R; Zwaan CM
    Leukemia; 2013 Mar; 27(3):735-7. PubMed ID: 22895118
    [No Abstract]   [Full Text] [Related]  

  • 52. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
    Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
    Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy.
    Hiller JK; Schmoor C; Gaidzik VI; Schmidt-Salzmann C; Yalcin A; Abdelkarim M; Blagitko-Dorfs N; Döhner K; Bullinger L; Duyster J; Lübbert M; Hackanson B
    Ann Hematol; 2017 Apr; 96(4):559-565. PubMed ID: 28058491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
    Takahashi K; Wang F; Kantarjian H; Doss D; Khanna K; Thompson E; Zhao L; Patel K; Neelapu S; Gumbs C; Bueso-Ramos C; DiNardo CD; Colla S; Ravandi F; Zhang J; Huang X; Wu X; Samaniego F; Garcia-Manero G; Futreal PA
    Lancet Oncol; 2017 Jan; 18(1):100-111. PubMed ID: 27923552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.
    Dang H; Jiang A; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Jan; 44(1):55-61. PubMed ID: 22939316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
    Oka S; Ono K; Nohgawa M
    Leuk Lymphoma; 2017 Oct; 58(10):2511-2513. PubMed ID: 28278708
    [No Abstract]   [Full Text] [Related]  

  • 57. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
    Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
    Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers.
    Meggendorfer M; Haferlach C; Zenger M; Macijewski K; Kern W; Haferlach T
    Leukemia; 2016 Jul; 30(7):1624-7. PubMed ID: 26859077
    [No Abstract]   [Full Text] [Related]  

  • 59. Selection of three miRNA signatures with prognostic value in non-M3 acute myeloid leukemia.
    Xue Y; Ge Y; Kang M; Wu C; Wang Y; Rong L; Fang Y
    BMC Cancer; 2019 Jan; 19(1):109. PubMed ID: 30700251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BRAF kinase domain mutations in de novo acute myeloid leukemia with monocytic differentiation.
    Xu Y; Wertheim G; Morrissette JJ; Bagg A
    Leuk Lymphoma; 2017 Mar; 58(3):743-745. PubMed ID: 27545333
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.